Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies
Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies
复制标题
DOI：
10.1159/000501856
复制
发表时间：
2019-11-01
影响因子：
5.7
通讯作者：
Lah, James J.
中科院分区：
文献类型：
--
作者：
Goetz, Margarethe E.;Hanfelt, John J.;Lah, James J.
随着预期寿命的增加，了解健康与老龄化之间的关系对于延缓发病率和最大限度地提高老龄人口的独立性至关重要。认知功能丧失是一种令人担忧的与年龄相关的疾病，也是一个日益增长的公共卫生问题。阿尔茨海默病（AD）是痴呆症的最常见原因，没有治愈性疗法。描述风险因素、生物标志物和AD进展之间的关系对于开发有效的疾病预测、临床干预以及最终的疾病预防至关重要。埃默里健康老龄化研究（EHAS）和埃默里健康脑研究（EHBS），这是嵌套在EHAS，旨在进一步了解健康老龄化和年龄相关疾病的发病机制，在良好的特征，基于社区的前瞻性队列，并确定生物标志物的最早表现的AD的促进预防性干预措施。EHAS是一项创新的、纵向的、基于网络的研究，招募了同意在未来研究中联系的美国讲英语的成年人。使用经过验证的工具，年度问卷询问人口统计学，社会经济学，自我报告的认知功能，个人和家族病史，生活方式和心理社会因素。认知评估也是使用移动设备获得的。EHBS嵌套在EHAS中，招募了多达2，500名EHAS参与者，年龄在50-75岁之间，没有AD，轻度认知障碍或任何其他记忆障碍的诊断。EHBS面对面，两年一次的研究访问，包括神经心理学测试，心血管测量，视网膜和大脑成像，生物标本采集（血液，脑脊液，肠道微生物组）和其他评估。自2016年春季以来，EHAS和EHBS分别招募了12，500名和863名参与者，并完成了基线评估。来自EHBS参与者的数据和生物标本将支持广泛的AD生物标志物发现工作，EHAS参与者的随访将能够评估自我报告的认知轨迹和各种健康状况的事件病例的积累。EHAS设计支持新研究仪器的间隔部署和辅助研究的目标采样。该项目将增加我们对健康老龄化的认识，提高我们对认知障碍和痴呆症风险因素的理解，支持生物标志物的开发，并促进包括AD在内的年龄相关疾病的研究。
Understanding the relationships between health and aging is essential for delaying morbidity and maximizing independence in aging populations as life expectancies increase. Loss of cognitive function is a feared age-associated condition and growing public health concern. Alzheimer's disease (AD), the most common cause of dementia, has no curative therapies. Characterizing the relationships between risk factors, biomarkers, and AD progression is critical for the development of effective disease prediction, clinical intervention, and ultimately, disease prevention. The Emory Healthy Aging Study (EHAS) and the Emory Healthy Brain Study (EHBS), which is nested within EHAS, aim to further the understanding of healthy aging and the pathogenesis of age-related illnesses in well-characterized, community-based prospective cohorts and to identify biomarkers for the earliest manifestations of AD for the facilitation of preventative interventions. The EHAS is an innovative, longitudinal, web-based study enrolling English-speaking adults in the U.S. who agree to be contacted for future studies. Using validated instruments, the annual questionnaire enquires about demographics, socioeconomics, self-reported cognitive function, personal and family medical history, lifestyle, and psychosocial factors. Cognitive assessments are also obtained using an ambulatory device. Nested within EHAS, the EHBS is enrolling up to 2,500 EHAS participants, 50-75 years old, who do not have a diagnosis of AD, mild cognitive impairment, or any other memory disorder. EHBS in-person, biennial study visits, include neuropsychological testing, cardiovascular measures, retinal and brain imaging, biospecimen collection (blood, cerebrospinal fluid, gut microbiome), and other assessments. Since spring 2016, EHAS and EHBS have enrolled 12,500 and 863 participants with completed baseline assessments, respectively. Data and biospecimens from EHBS participants will support a broad range of AD biomarker discovery efforts, and follow-up of EHAS participants will enable assessment of self-reported cognitive trajectories and accumulation of incident cases of a variety of health conditions. The EHAS design supports the interval deployment of new study instruments and targeted sampling for ancillary studies. This project will increase our knowledge about healthy aging, improve our understanding of risk factors for cognitive impairment and dementias, support development of biomarkers, and facilitate studies of age-associated disorders including AD.